Anluohuaxian
PreclinicalSmall molecule
Anluohuaxian is one of 6 small molecule programs targeting Hepatic fibrosis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Hepatic Fibrosis
#DrugCompanyPhaseTrials
1Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
BMS-986263
Bristol-Myers SquibbPhase 2
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Daas
TThird Affiliated Hospital, Sun Yat-Sen University
Preclinical
Anluohuaxian
PPeking University First Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anluohuaxian. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University First Hospital